AIM
SLDB icon

Alambic Investment Management’s Solid Biosciences SLDB Stock Holding History

Alambic Investment Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,164
Closed -$78K – 263
2019
Q4 		$78K Buy
+1,164
New +$128K 0.07% 255

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Alambic Investment Management's SLDB Position: Q1 2020 in Review

Alambic Investment Management sold out of Solid Biosciences (SLDB) in Q1 2020, closing a stake of 1,164 shares — an estimated $78K sold.

Alambic Investment Management first reported a position in SLDB in Q4 2019 and held it in 1 quarter. The position peaked at $78K in Q4 2019. 71 funds tracked by Wall St. Rank hold SLDB as of Q1 2020.

  • Alambic Investment Management reported no remaining Solid Biosciences position as of Q1 2020 after selling out during the quarter.
  • Alambic Investment Management sold 1,164 Solid Biosciences shares in Q1 2020, an estimated $78K.
  • Alambic Investment Management first reported a position in Solid Biosciences in Q4 2019 and held it in 1 quarter.
  • Alambic Investment Management's Solid Biosciences position peaked at $78K in Q4 2019.
  • 71 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2020.

Based on Alambic Investment Management's 13F filing for Q1 2020, filed 11 May 2020.